Lisaftoclax is a novel Bcl-2 inhibitor developed by Ascentage Pharma. In November 2024, the New Drug Application (NDA) for lisaftoclax for the treatment of R/R chronic lymphocytic leukemia/small ...

Lisaftoclax is a novel Bcl-2 inhibitor developed by Ascentage Pharma. In November 2024, the New Drug Application (NDA) for lisaftoclax for the treatment of R/R chronic lymphocytic leukemia/small ...

announced that it has released the latest data from a Phase Ib/II study of the investigational Bcl-2 inhibitor, lisaftoclax (APG-2575), in combination with hypomethylating agent azacitidine in ...

Update 6/3: A spokesperson for Warner Bros. has denied that Michael Bay was being considered to direct Man of Steel 2. Bay is known for his action blockbusters, having directed the first two Bad ...

Update 6/3: A spokesperson for Warner Bros. has denied that Michael Bay was being considered to direct Man of Steel 2. Original story: It looks like Christopher McQuarrie wasn’t the only ...

AIMS To study the expression of Bcl-2, Bcl-x, as well the presence of cleaved caspase-3 in neurofibromas and malignant peripheral nerve sheath tumors. The expression of Bcl-2 and Bcl-x and the ...

In particular, activated human HSC/MFs in culture overexpressed Bcl-2. The role of Bcl-2 was crucial as Bcl-2 silenced cells became susceptible to TNF-α induced apoptosis. Finally, Bcl-2 was markedly ...

This solid study assesses a mitochondrial polymerase inhibitor in combination with the BCL-2 inhibitor venetoclax, with the aim to increase the elimination of acute myeloid leukemia. It provides ...

Bcl-2; antibacterial; antioxidant; DNA damage; HeLa; Physalis I Department of Molecular Biology and Genetic, Faculty of Science, Istanbul University, Vezneciler, Istanbul, Turkey, e-mail: ...